Clinical Trial

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2026-01-08; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07332091
Lead Sponsor CSL Behring
Conditions Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Enrollment 84 participants
Start Date 2026-01-22
Primary Completion 2028-03-06 (estimated)
Study Completion 2028-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-03